Climb Bio, Inc.
Industry
- Pharmaceuticals
- Biotechnology
Other Names/Subsidiaries
- Eliem Therapeutics
- Eliem Therapeutics (UK)
- Athenen Therapeutics
- NeoKera
- Tenet Medicines.
Latest on Climb Bio, Inc.
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With UK’s Alchemab On A
Alumis, Inc. planned to raise between $282.4m and $317.7m in the last biopharmaceutical initial public offering in the US during the first half of 2024, but instead grossed $250m on 27 June from the
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. In this edition of Deal Watch, we highl
US initial public offerings by biopharmaceutical companies appear to be on the rise in 2024 with nine during the first quarter, including Boundless Bio Inc. ’s $100m IPO on 27 March, outpacing 2023 w